Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pyxis Oncology Inc (NQ: PYXS )

1.640 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 64,000
Open 1.630
Bid (Size) 1.620 (8)
Ask (Size) 1.670 (3)
Prev. Close 1.640
Today's Range 1.620 - 1.680
52wk Range 1.100 - 6.920
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
Dr. Kobayashi brings over 25 years of experience in oncology drug development, including Antibody Drug Conjugates (ADCs) and other oncology modalities 
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
From Pyxis Oncology
Via GlobeNewswire

Performance

YTD
+18.84%
+18.84%
1 Month
-5.75%
-5.75%
3 Month
-26.79%
-26.79%
6 Month
-49.23%
-49.23%
1 Year
+27.13%
+27.13%

More News

Read More
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
Via FinancialNewsMedia
Exposures Product Safety
NASDAQ:PYXS Investor Notice: Investigation over Possible Securities Laws Violations by Pyxis Oncology, Inc.
Via SBWire
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst
Via Benzinga
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
From Pyxis Oncology
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 5, 2023
Via Benzinga
Pyxis Oncology Successfully Completes Acquisition of Apexigen
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
From Pyxis Oncology
Via GlobeNewswire
Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
From Pyxis Oncology
Via GlobeNewswire
Small SPAC Biotech Apexigen To Be Acquired Pyxis Oncology For $16M
Via Benzinga
Pyxis Oncology Bolsters Oncology Portfolio Through $16M Apexigen Acquisition
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Why Is Apexigen (APGN) Stock Up 31% Today?
Via InvestorPlace
Why Chicken Soup For The Soul Entertainment Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Top 5 Health Care Stocks That May Collapse
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Shift Technologies Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.